Beyond preclinical promise: can mesenchymal stromal cell-derived extracellular vesicles reliably target tubular epithelial cells?

Abstract

Kidney disease, encompassing both acute kidney injury (AKI) and chronic kidney disease (CKD), represents a major global health challenge. A pivotal aspect of the pathogenesis of these conditions is damage to renal tubular epithelial cells (TECs), which contributes to maladaptive repair mechanisms and fibrosis. Due to their essential role, TECs are regarded as a promising target for innovative therapeutic strategies. Mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) have attracted increasing attention for their therapeutic potential in kidney disease, with extensive literature documenting their beneficial effects on TEC damage through targeted mechanisms. In this review, we critically examine the existing literature on the targeting of TECs by MSC-EVs in both in vitro and in vivo settings. Furthermore, we highlight the limitations and potential of MSC-EV-based strategies for TEC targeting, aiming to provide insights for future clinical trials and therapeutic applications.

Keywords

Kidney disease / mesenchymal stem/stromal cells / extracellular vesicles / tubular epithelial cells / targeting / biodistribution

References

[1] Kosanović M,Glamočlija S,Ortiz A.Extracellular vesicles and acute kidney injury: potential therapeutic avenue for renal repair and regeneration.IJMS2022;23:3792 PMCID:PMC8998560

[2] Reiss AB,Zubair A,Johnson M.Fibrosis in chronic kidney disease: pathophysiology and therapeutic targets.JCM2024;13:1881 PMCID:PMC11012936

[3] Foreman KJ,Dolgert A.Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories.Lancet2018;392:2052-90 PMCID:PMC6227505

[4] Qi R.Renal tubular epithelial cells: the neglected mediator of tubulointerstitial fibrosis after injury.Cell Death Dis2018;9:1126 PMCID:PMC6233178

[5] Li ZL,Zhou Y,Lv LL.Renal tubular epithelial cells response to injury in acute kidney injury.EBioMedicine2024;107:105294 PMCID:PMC11388183

[6] Zou Y,Lok SWY.Tubular FoxP2 and kidney fibrosis.J Am Soc Nephrol2025;36:544-58 PMCID:PMC11975242

[7] Lake BB, Menon R, Winfree S, et al; KPMP Consortium. An atlas of healthy and injured cell states and niches in the human kidney. Nature. 2023;619:585-94.

[8] Clark JZ,Chou CL,Lee JW.Representation and relative abundance of cell-type selective markers in whole-kidney RNA-Seq data.Kidney Int2019;95:787-96 PMCID:PMC7466803

[9] Balzer MS,Susztak K.How many cell types are in the kidney and what do they do?.Annu Rev Physiol2022;84:507-31 PMCID:PMC9233501

[10] Koh ES.Recent update on acute kidney injury-to-chronic kidney disease transition.Yonsei Med J2024;65:247-56 PMCID:PMC11045347

[11] Liu BC,Lv LL.Renal tubule injury: a driving force toward chronic kidney disease.Kidney Int2018;93:568-79

[12] Zhou J.Mesenchymal stem/stromal cells (MSCs): origin, immune regulation, and clinical applications.Cell Mol Immunol2023;20:555-7 PMCID:PMC10229593

[13] Lazarus HM,Gerson SL,Caplan AI.Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use.Bone Marrow Transplant1995;16:557-64

[14] Ceccotti E,Camussi G.Mesenchymal stem cells derived extracellular vesicles for chronic kidney disease: pleiotropic mechanisms of actions of a versatile therapy.Front Bioeng Biotechnol2025;13:1612193 PMCID:PMC12202407

[15] Zheng Y,Li X,Fan J.Extracellular vesicles in chronic kidney disease: diagnostic and therapeutic roles.Front Pharmacol2024;15:1371874 PMCID:PMC10965796

[16] Kosanović M,Kutzner TJ,Bozic M.Clinical prospect of mesenchymal stromal/stem cell-derived extracellular vesicles in kidney disease: challenges and the way forward.Pharmaceutics2023;15:1911 PMCID:PMC10384614

[17] Welsh JA, Goberdhan DCI, O'Driscoll L, et al; MISEV Consortium. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024;13:e12404. PMCID:PMC10850029

[18] Barr SI,Bessa SS.Role of exosomes in pathogenesis, diagnosis, and treatment of diabetic nephropathy.BMC Nephrol2025;26:230 PMCID:PMC12063312

[19] Battistelli M.Apoptotic bodies: particular extracellular vesicles involved in intercellular communication.Biology2020;9:21 PMCID:PMC7168913

[20] Witwer KW,Bruno S.Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications.J Extracell Vesicles2019;8:1609206 PMCID:PMC6493293

[21] Tang T,Crowley SD,Liu B.Shedding light on the role of extracellular vesicles in renal fibrosis.Fundam Res2024;Epub ahead of print:

[22] Huang Y.Mesenchymal stem cells and extracellular vesicles in therapy against kidney diseases.Stem Cell Res Ther2021;12:219 PMCID:PMC8011150

[23] Birtwistle L,Pollock C.Mesenchymal stem cell-derived extracellular vesicles to the rescue of renal injury.Int J Mol Sci2021;22:6596 PMCID:PMC8235408

[24] Convento MB,Boim MA.Umbilical cord mesenchymal stem cell-derived extracellular vesicles as natural nanocarriers in the treatment of nephrotoxic injury in vitro.Cells2024;13:1658 PMCID:PMC11475496

[25] Cao JY,Tang TT.Exosomal miR-125b-5p deriving from mesenchymal stem cells promotes tubular repair by suppression of p53 in ischemic acute kidney injury.Theranostics2021;11:5248-66 PMCID:PMC8039965

[26] Hong S,Kim J,Park TS.Extracellular vesicles from induced pluripotent stem cell-derived mesenchymal stem cells enhance the recovery of acute kidney injury.Cytotherapy2024;26:51-62

[27] Yin S,Ren D.Mesenchymal stem cell-derived exosomes attenuate epithelial-mesenchymal transition of HK-2 cells.Tissue Eng Part A2022;28:651-9

[28] Bian Z,Zhu R.miR-21-5p in extracellular vesicles obtained from adipose tissue-derived stromal cells facilitates tubular epithelial cell repair in acute kidney injury.Cytotherapy2023;25:310-22

[29] Liang M,Zheng D,Jin J.Exosomes from miR-374a-5p-modified mesenchymal stem cells inhibit the progression of renal fibrosis by regulating MAPK6/MK5/YAP axis.Bioengineered2022;13:4517-27 PMCID:PMC8973867

[30] Wang W,Liao D.Effects and mechanisms of extracellular vesicles in different models of acute kidney injury.Stem Cells Int2025;2025:1075016 PMCID:PMC11957863

[31] Lindoso RS,Bruno S.Extracellular vesicles released from mesenchymal stromal cells modulate miRNA in renal tubular cells and inhibit ATP depletion injury.Stem Cells Dev2014;23:1809-19 PMCID:PMC4103261

[32] Tomasoni S,Rota C.Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells.Stem Cells Dev2013;22:772-80 PMCID:PMC3578372

[33] Mao J,Wu F.MSC-EVs transferring mitochondria and related components: a new hope for the treatment of kidney disease.Front Immunol2022;13:978571 PMCID:PMC9556818

[34] Yu Y,Guo Q.Human umbilical cord mesenchymal stem cell exosome-derived miR-874-3p targeting RIPK1/PGAM5 attenuates kidney tubular epithelial cell damage.Cell Mol Biol Lett2023;28:12 PMCID:PMC9903493

[35] Tang TT,Li ZL.Kim-1 targeted extracellular vesicles: a new therapeutic platform for RNAi to Treat AKI.J Am Soc Nephrol2021;32:2467-83 PMCID:PMC8722800

[36] Huang TY,Su WT.Therapeutic potential of pretreatment with exosomes derived from stem cells from the apical papilla against cisplatin-induced acute kidney injury.Int J Mol Sci2022;23:5721 PMCID:PMC9146099

[37] Li JK,Su Y.Mesenchymal stem cell-derived extracellular vesicles: a potential therapeutic strategy for acute kidney injury.Front Immunol2021;12:684496 PMCID:PMC8209464

[38] Nho JH,Lee MJ.Beneficial effects of cynaroside on cisplatin-induced kidney injury in vitro and in vivo.Toxicol Res2018;34:133-41 PMCID:PMC5903139

[39] Wang SY,Hong Q,Cai GY.Mesenchymal stem cells ameliorate cisplatin-induced acute kidney injury via let-7b-5p.Cell Tissue Res2023;392:517-33

[40] Liang J.Animal models of kidney disease: challenges and perspectives.Kidney3602023;4:1479-93 PMCID:PMC10617803

[41] Wang B,Zhang B.Pre-incubation with hucMSC-exosomes prevents cisplatin-induced nephrotoxicity by activating autophagy.Stem Cell Res Ther2017;8:75 PMCID:PMC5385032

[42] Zhao M,Wang C.Mesenchymal stem cell-derived extracellular vesicles attenuate mitochondrial damage and inflammation by stabilizing mitochondrial DNA.ACS Nano2021;15:1519-38

[43] Lopes JA,Rodrigues-Ferreira C.Early effects of extracellular vesicles secreted by adipose tissue mesenchymal cells in renal ischemia followed by reperfusion: mechanisms rely on a decrease in mitochondrial anion superoxide production.Int J Mol Sci2022;23:2906 PMCID:PMC8955255

[44] Mu YF,Pan SK.Macrophage-driven inflammation in acute kidney injury: therapeutic opportunities and challenges.Transl Res2025;278:1-9

[45] Eirin A,Puranik AS.Mesenchymal stem cell-derived extracellular vesicles attenuate kidney inflammation.Kidney Int2017;92:114-24 PMCID:PMC5483390

[46] Guo Q,Chen M.Exosomes from human umbilical cord stem cells suppress macrophage-to-myofibroblast transition, alleviating renal fibrosis.Inflammation2024;47:2094-107

[47] Jeon JS,Bae YU.microRNA in extracellular vesicles released by damaged podocytes promote apoptosis of renal tubular epithelial cells.Cells2020;9:1409 PMCID:PMC7349539

[48] Kang M,Blenkiron C.Biodistribution of extracellular vesicles following administration into animals: a systematic review.J Extracell Vesicles2021;10:e12085 PMCID:PMC8224174

[49] Liu Y,Wang H.Enhanced therapeutic effects of MSC-derived extracellular vesicles with an injectable collagen matrix for experimental acute kidney injury treatment.Stem Cell Res Ther2020;11:161 PMCID:PMC7178991

[50] Malvicini R,Tolomeo AM.Influence of the isolation method on characteristics and functional activity of mesenchymal stromal cell-derived extracellular vesicles.Cytotherapy2024;26:157-70

[51] Llorens-Revull M,Quer J.Comparison of extracellular vesicle isolation methods for miRNA sequencing.Int J Mol Sci2023;24:12183 PMCID:PMC10418926

[52] Clos-Sansalvador M,Roura S,Borràs FE.Commonly used methods for extracellular vesicles’ enrichment: implications in downstream analyses and use.Eur J Cell Biol2022;101:151227

[53] Wang SJ,Chen FW.Bone marrow mesenchymal stem cell-derived extracellular vesicles containing miR-181d protect rats against renal fibrosis by inhibiting KLF6 and the NF-κB signaling pathway.Cell Death Dis2022;13:535 PMCID:PMC9174332

[54] Gupta D,El Andaloussi S.Dosing extracellular vesicles.Adv Drug Deliv Rev2021;178:113961

[55] Noda P,Teles F.Extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs) as adjuvants in the treatment of chronic kidney disease (CKD).Cells2025;14:434 PMCID:PMC11941753

[56] Zou X,Xing X,Gong D.Human mesenchymal stromal cell-derived extracellular vesicles alleviate renal ischemic reperfusion injury and enhance angiogenesis in rats.Am J Transl Res2016;8:4289-99 PMCID:PMC5095321

[57] Hu X,Liu A.Bone marrow mesenchymal stem cell-derived exosomal miR-34c-5p ameliorates RIF by inhibiting the core fucosylation of multiple proteins.Mol Ther2022;30:763-81 PMCID:PMC8821970

[58] Shi L,Zeng H.Mesenchymal stem cell-derived extracellular vesicles ameliorate renal interstitial fibrosis via the miR-13474/ADAM17 axis.Sci Rep2024;14:17703 PMCID:PMC11291924

[59] Zhang X,Ge R.Arg-Gly-Asp engineered mesenchymal stem cells as targeted nanotherapeutics against kidney fibrosis by modulating m6A.Acta Biomater2025;198:85-101

[60] Gao Z,Peng F.Hypoxic mesenchymal stem cell-derived extracellular vesicles ameliorate renal fibrosis after ischemia-reperfusion injure by restoring CPT1A mediated fatty acid oxidation.Stem Cell Res Ther2022;13:191 PMCID:PMC9080148

[61] Cao H,Gao H.In vivo tracking of mesenchymal stem cell-derived extracellular vesicles improving mitochondrial function in renal ischemia-reperfusion injury.ACS Nano2020;14:4014-26

[62] Cui C,Song J.Exosomes derived from mesenchymal stem cells attenuate diabetic kidney disease by inhibiting cell apoptosis and epithelial-to-mesenchymal transition via miR-424-5p.FASEB J2022;36:e22517

[63] Kim H,Kim S.Extracellular vesicles from induced mesenchymal stem cells inhibit acute kidney injury to chronic kidney disease transition.Int J Stem Cells2025;18:286-300 PMCID:PMC12394081

[64] Kim SH,Lee CH.Glycoengineered stem cell-derived extracellular vesicles for targeted therapy of acute kidney injury.Biomaterials2025;318:123165

[65] Deng XH,Sun Q.The effects of Klotho delivering mesenchymal stem cell-derived small extracellular vesicles on acute kidney injury.J Nanobiotechnology2025;23:427 PMCID:PMC12144696

[66] Yang Y,Zhang Y,Li L.Exosomes derived from mesenchymal stem cells ameliorate renal fibrosis via delivery of miR-186-5p.Hum Cell2022;35:83-97

[67] Matsushita K,Akane H,Ogawa K.Role of CD44 expressed in renal tubules during maladaptive repair in renal fibrogenesis in an allopurinol-induced rat model of chronic kidney disease.J Appl Toxicol2024;44:455-69

[68] Huang Y,Jiang K.Improving kidney targeting: the influence of nanoparticle physicochemical properties on kidney interactions.J Control Release2021;334:127-37 PMCID:PMC8192458

[69] Huang Y,Ahrari S.Physiological principles underlying the kidney targeting of renal nanomedicines.Nat Rev Nephrol2024;20:354-70

[70] Cheng HT,Hsia T.A quantitative review of nanotechnology-based therapeutics for kidney diseases.Wiley Interdiscip Rev Nanomed Nanobiotechnol2024;16:e1953